Clinical Trials
52 trialsKL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
Sichuan Baili Pharmaceutical Co., Ltd.
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Genmab
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
Shanghai Miracogen Inc.
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Novartis
Magic-C002
Shanghai Miracogen Inc.
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
MediLink Therapeutics (Suzhou) Co., Ltd.
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
Shanghai Henlius Biotech
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Akeso
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Viracta Therapeutics, Inc.
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
Akeso
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
Akeso
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics, Inc.
ROOT
Taproot Health
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
PDL1x41BB
Inhibrx Biosciences, Inc
A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
Akeso
DUET-3
Xencor, Inc.
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.
Jiangsu HengRui Medicine Co., Ltd.
A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Cullinan Therapeutics Inc.
VANCE
Tessa Therapeutics
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Atara Biotherapeutics
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
DUET-4
Xencor, Inc.
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
DUET-2
Xencor, Inc.
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
Ascentage Pharma Group Inc.
A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Novartis
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
CytoMed Therapeutics Pte Ltd
Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
Jiangsu HengRui Medicine Co., Ltd.
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Celgene